Billionaire's Match (Khloe and Nick Hunt) novel Chapter 983

The next day, explosive business news swept through Goldmont City.

Investors from the royal family of Yustonia had established a new company in Goldmont City—Olympus. From the outset, it made a splash, securing multiple top-tier national projects with massive investment, all concentrated in pharmaceuticals and energy.

This immediately hit the headlines because, domestically—and especially in Goldmont City—these two sectors had long been monopolized by Morrison Group and Hunt Group.

As expected, Hunt Group's recently acquired new energy project had its downstream partnerships abruptly cut off by Olympus. Meanwhile, Morrison Group's new drug, still under development, had its competing product preemptively announced by Olympus, scheduled to hit the market a full month earlier than planned.

Industry leaders scrambled to uncover Olympus's background. The company, however, was not hiding. Reports soon confirmed it had registered capital exceeding a billion dollars, fully funded by Yustonia's royal family investment fund.

A spokesperson for Olympus stated publicly that the Yustonia royal fund held great confidence in Goldmont City's business environment and market potential. They promised to introduce internationally leading R&D technologies and capital management models, partnering with local enterprises to grow the market and achieve mutual benefits.

The words sounded polished, but everyone read between the lines: this was a direct strike. They had targets, and they were coming to take them down.

The news immediately sent shockwaves through the industry. By that afternoon, the stock prices of Morrison Group and Hunt Group had plunged significantly.

What drew even more attention was Olympus's office location: in the newly completed New Financial City, strategically positioned between Hunt Group and Morrison Group. From the penthouse windows, both corporate towers were fully in view—a choice industry insiders interpreted as loaded with meaning.

…

By evening, the atmosphere in Morrison Group's top-floor boardroom was tense.

Ethan sat at the head of the table, a tablet in front of him looping the latest Olympus news. He had just finished a project meeting when the alert arrived: Olympus's newly announced drugs were targeting confidential projects that Morrison Group had only recently completed—projects still awaiting regulatory approval.

VERIFYCAPTCHA_LABELVerify